Phil Clarke, PhD

Phil Clarke, PhD, is an associate director of scientific communications at ChemPartner, where he supports both scientific and commercial teams through troubleshooting, project management of chemistry programs, and the generation of scientific content.
Clarke completed his PhD in synthetic organic chemistry at the University of Southampton in 2003, under the supervision of Bruno Linclau, PhD, focusing on asymmetric Diels–Alder methodology. Prior to joining ChemPartner, he held leadership roles at Concept Life Sciences and Charnwood Discovery, where he managed drug discovery projects, developed high-performing teams, and delivered innovative chemistry solutions across a range of therapeutic areas.

With over two decades of experience in chemistry and scientific strategy, he brings a deep understanding of drug development and a passion for translating complex science into impactful communication.

Greg Liang, MD, MSc

Greg Liang, MD, MSc, graduated from Bethune Medical University and Chinese Academy of Medical Sciences, majored in nuclear medicine and biochemistry, and worked for several biotech companies in the U.S. Liang has over thirty years’ experience in monoclonal antibody development, immunoassays method and product development, antibody and conjugated drug development, and cell therapeutic drug development. Since 2017, he has led a team that built up a comprehensive ChemPartner ADC conjugation and development team, also coordinated work with the linker-payload, antibody discovery, immune oncology, DMPK, and CMC teams, and established an integrated XDC development service platform.

Hu Liu, PhD

Hu Liu holds a PhD in molecular immunology from China Agricultural University and is a scientific leader in immunology and oncology, with extensive experience in both academic and industrial settings. Currently serving as senior director at Shanghai ChemPartner, Hu has successfully led teams and managed over 100 integrated antibody discovery projects, significantly contributing to the development of multiple new antibody platform capabilities over the past decade. Many of the projects he has been involved in have progressed to late-stage clinical development.